Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

transcreation

- PMLiVE

Bristol Myers Squibb gains rights to SystImmune’s ADC candidate for up to $8.4bn

BL-B01D1 has shown promise against a range of solid tumours including lung cancer

- PMLiVE

Almirall and etherna partner to develop mRNA-based therapies for severe skin diseases

Dermatological diseases are estimated to affect 1.8 billion people worldwide

- PMLiVE

FDA grants fast track designation to Candel’s immunotherapy in pancreatic cancer

The disease is the fourth leading cause of cancer-related death in the US, accounting for 3.3% of new cancer cases

- PMLiVE

Reimagining scientific publications

By Sam Kew

Hear from her: A Passionate Cause: Elevating Women to Reshape Medicine

Medscape Education

Hear from her: Women’s Health Faces Some Difficult Headwinds. Here’s How We Can Move Forward

Wilmington Healthcare

Hear from her: A “Leaky Pipeline” and the Loss of Talented Female Physicians

Medscape Education

Hear from Her: Planting the Seeds for Future Women Leaders in Medicine

Medscape Education

- PMLiVE

BOLDSCIENCE launches BOLDAPPROVALS division

BOLDAPPROVALS, a new division of the medical communications agency BOLDSCIENCE, will help pharmaceutical and biotech clients gain regulatory approval with comprehensive services that include preparation for US Food and Drug...

BOLDSCIENCE

- PMLiVE

AstraZeneca to acquire vaccine developer Icosavax in deal worth up to $1.1bn

The transaction includes a vaccine candidate targeting two causes of severe respiratory infection

- PMLiVE

GSK’s Jemperli combination receives EC approval for endometrial cancer

Up to 20% of endometrial cancer patients will have advanced disease at the time of diagnosis

- PMLiVE

CAR-T therapy shown to improve symptoms of autoimmune diseases

All patients stopped taking immune-suppressive drugs after receiving the therapy

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links